The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15%

In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers.

London

Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings.

DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics.

To request a sample copy / brochure of this report, please visit link
https://www.rootsanalysis.com/....reports/dna-and-gene

Key Market Insights

Around 80 companies claim to offer DNA and gene cloning services, globally
Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers.

Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning
Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning.


Over 1,350 patents related to DNA and gene cloning in biopharmaceutical industry have been filed / granted since 2017
Owing to the increase in research and development efforts by various industry and non-industry players engaged in this domain, close to 60% of patent applications have been filed post-2018. It is worth noting that 57% patents related to DNA and gene cloning have been filed by non-industry players.

Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018
More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences.

Over 35 global events related to DNA and gene cloning have been organized since 2017
Majority of the events related to DNA and gene cloning were organized in Asia-Pacific (64%). It is worth highlighting that the agendas of the events organized post-2020 include discussions on the potential, advancements and challenges associated with DNA and gene cloning techniques.

For additional details, please visit
https://www.rootsanalysis.com/....reports/dna-and-gene
or email [email protected]

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The human microbiome market is anticipated to grow at a CAGR of 24% till 2035

With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications.


Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings.

The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/281/request-

Key Market Insights

Over 230 drug candidates are currently being developed by more than 70 drug developers
Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders.

FMTs are the only commercially available microbiome therapies approved by the FDA
These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications.

Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021
Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period.

More than USD 1 billion has been invested by both private and public investors, since 2017
Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million.

Outsourcing has become an integral part of the microbiome and live biotherapeutics development process
Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe.


For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen or email [email protected]

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

 

www.rootsanalysis.com

Request Sample - The Human Microbiome Market | Market Size | Industry Analysis | 2035

The human microbiome report features an informed opinion on the likely adoption of microbiome-based therapeutics, diagnostics and FMTs, in...

Oral Proteins and Peptides Market

Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics.

Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/192/request-


Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future.


For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen or email [email protected]

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035

An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries.

Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings.

Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/needlestick-

Key Market Insights

Currently, around 120 needlestick safety injection devices are available in the market
More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections.

Over 50 companies claim to develop needlestick safety injection devices, worldwide
Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%).

Partnership activity within this field has grown significantly between 2020 and 2022
Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions.

Over USD 260 million has been invested by both private and public investors, since 2016
Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain.

Close to 20 global events were organized in the past couple of years in this industry
Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries.

More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018
Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes.

For additional details, please visit https://www.rootsanalysis.com/....reports/needlestick- or email [email protected]


You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The cell invasion and migration assays market is projected to grow at a CAGR of 8%

In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products.

London
Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings.
Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/cell-invasio


Key Market Insights
Presently, more than 80% of the total assay providers are based in North America
This segment of the industry is dominated by the presence of companies that were established pre-2000 (64%), followed by firms established during 2000-2010 (27%). In addition, most of the players engaged in this domain are small firms (less than 100 employees), representing over 45% of the total assay providers.

Currently, over 80 cell invasion and migration assays are available in the market
It is worth noting that most of the cell invasion and migration assays are currently being used for tumor studies (89%), followed by those employed for screening purposes (79%). Further, most of the assays are being developed for adherent cell cultures (48%), followed by those being manufactured for both adherent and suspension cell cultures (40%).

55% players claim to be capable of offering both cell invasion as well as cell migration assays
64% of the cell invasion and migration assays can be stored under frozen temperature (-18°C to -40°C), followed by those stored under refrigerated conditions (+1°C to +18°C) (36%). Further, it is worth noting that most of the cell invasion and migration assays are being used to conduct 100 tests (37%). This was followed by assays being developed to conduct 12 (35%) and 96 tests (23%).

Over 650 articles focused on cell invasion and migration assays have been published, since 2021
Majority of the scientific literature published in this domain was focused on research (96%), followed by review articles (4%). It is worth mentioning that articles related to cell invasion and migration assays have been affiliated by over 300 universities.

Patents filed / granted for cell invasion and migration assays have increased at a CAGR of more than 45%, since 2017
Of the total, around 55% of the patents were applications, followed by those that have been granted approval (45%). Around 63% of these intellectual property documents were filed / granted in North America; with the maximum number of patents having been filed in the US, since 2017.

For additional details, please visit
https://www.rootsanalysis.com/....reports/cell-invasio

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/